Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co 2020 Financial Guidance Call Transcript

Dec 17, 2019 / 02:00PM GMT
Release Date Price: R$17.01 (+1.73%)
Operator

[Ladies] and gentlemen, thank you for standing by, and welcome to the 2020 Guidance Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the call over to your host, Kevin Hern, Vice President of Investor Relations. Please go ahead.

Kevin Hern
Eli Lilly and Company - VP of IR

Good morning. Thank you for joining us for Eli Lilly and Company's 2020 Financial Guidance Call. I'm Kevin Hern, Vice President of Investor Relations. Joining me on today's call are Dave Ricks, Lilly's Chairman and CEO; Josh Smiley, Chief Financial Officer; Dr. Dan Skovronsky, President of Lilly Research Laboratories; Anne White, President of Lilly Oncology; Patrik Jonsson, President of Lilly Biomedicines; Mike Mason, incoming President of Lilly Diabetes; and Jake Van Naarden, Chief Operating Officer, Loxo Oncology at Lilly. We're also joined by Kim Macko and Mike Czapar of the Investor Relations team.

During this conference call, we anticipate making projections and forward-looking statements based on our current

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot